Reuters logo
BRIEF-‍Myriad Genetics announces new positive results for EndoPredict
October 26, 2017 / 11:47 AM / 23 days ago

BRIEF-‍Myriad Genetics announces new positive results for EndoPredict

Oct 26 (Reuters) - Myriad Genetics Inc

* Endopredict (epclin) shown in second study to be more effective than oncotype dx® (rs) in women with intermediate risk of breast cancer recurrence

* Myriad genetics inc - ‍announced new positive results for endopredict, a second-generation prognostic gene expression test for breast cancer​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below